The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
Patents, Royalties, Other Intellectual Property - Co-inventor on technologies that have been licensed to Forty Seven Inc
 
Consulting or Advisory Role - Agios; Celyad
Speakers' Bureau - Abbvie; Agios; Celgene; Incyte; Novartis
Research Funding - Celgene
Patents, Royalties, Other Intellectual Property - Intellectual property patent for LB-100 in MDS
The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.
 
David Andrew Sallman
No Relationships to Disclose
 
William Bruce Donnellan
No Relationships to Disclose
 
Adam Steven Asch
Research Funding - AML40 5F9003; AML40 5F9005; SCRI_AML22_2215-CL-0103x09A Phase I Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia; SCRI_HR41_D6130C00003x09A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticle in Patients with Relapsed Acute Myeloid Leukaemia/High-Risk Myelodysplastic Syndrome or T; SCRI_HR44_INCB 53914-101x09A Phase I/II Study of INCB053914 in Subjects with Advanced Malignancies; SCRI_HR47_MEDI4736-NHL-001x09A Phase I/II, Open-Label, Multicenter Study to Assess the Safety and Tolerability of Durvalumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination Therapy in Subjects with Lymphoma or Chronic Lymphocytic Leukemia; SCRI_LYM128_ME-401-002x09A Phase Ib, Open-Label, Dose Escalation Study of ME-401 in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL)
Patents, Royalties, Other Intellectual Property - Spouse has filed provisional patent re: prognostic/predictive prostate cancer gene signature (I)
 
Daniel Junseung Lee
Consulting or Advisory Role - Boston Biomedical
Research Funding - Abbvie/Genentech (Inst); Bayer (Inst); Forty Seven (Inst); Tolero Pharmaceuticals (Inst)
 
Monzr Al Malki
No Relationships to Disclose
 
Guido Marcucci
No Relationships to Disclose
 
Daniel Aaron Pollyea
Consulting or Advisory Role - Abbvie; Agios; argenx; Astellas Pharma; Celgene; Celyad; Curis; Daiichi Sankyo; Gilead Sciences; Glycomimetics; Pfizer; SERVIER; Takeda
Research Funding - Agios (Inst); Pfizer (Inst)
 
Suman Kambhampati
No Relationships to Disclose
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Celgene; Novartis
Speakers' Bureau - Alexion Pharmaceuticals; Novartis
Research Funding - Boehringer Ingelheim (Inst); Celgene (Inst); Eleos (Inst); GlaxoSmithKline (Inst); Incyte (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Celgene; Incyte; Novartis
 
Joanna Van Elk
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Menlo Therapeutics; Portola Pharmaceuticals
Consulting or Advisory Role - Forty Seven
Travel, Accommodations, Expenses - Forty Seven
 
Ming Lin
Employment - Forty Seven; Gilead Sciences
Stock and Other Ownership Interests - Forty Seven; Gilead Sciences
 
Balaji Agoram
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
 
James Y Chen
Employment - Forty Seven
Stock and Other Ownership Interests - Forty Seven
Consulting or Advisory Role - Forty Seven
Research Funding - Forty Seven
Travel, Accommodations, Expenses - Forty Seven
 
Jens-Peter Volkmer
No Relationships to Disclose
 
Chris H.M. Takimoto
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Patent Proposals filed relating to using anti-CD47 antibodies as cancer therapy at my current company of employment, Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Mark Chao
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Hepatx
Honoraria - D2G Oncology
Consulting or Advisory Role - Chimera Bioengineering
Patents, Royalties, Other Intellectual Property - I am an inventor on several patents from Stanford University that have been licensed to Forty Seven, Inc. I am also an inventor on patents generated from Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Paresh Vyas
Stock and Other Ownership Interests - OxStem
Honoraria - Abbvie; Celgene; Daiichi Sankyo; Pfizer
Patents, Royalties, Other Intellectual Property - Associated with a patent, do no receive royalties
Travel, Accommodations, Expenses - Abbvie; Celgene; Daiichi Sankyo; Pfizer